Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
265.4 USD | +0.52% | -1.72% | -7.87% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.